KUALA LUMPUR: Duopharma Biotech Bhd
posted a net profit of RM88.56mil in the nine-month period to Sept 30, 2026, as compared to RM68.42mil in the year-ago period, due to strong profit margins that offset a weaker topline.
According to the pharmaceutical group's results filing with Bursa Malaysia, profit margins were supported by a more favourable product mix and lower imported active pharmaceutical ingredient (API) costs amid the strengthening of the ringgit.
Revenue in 9M26 was RM692.29mil, down from RM707.01mil in 9M25, primarily attributable to the normalisation of public sector insulin sales following the exceptional sales recorded in the first half of 2025.
"Underlying business growth remained positive, supported by sustained demand from the export segments and private market, alongside stronger contributions from the Ethical Specialty and Consumer Healthcare businesses," it added.
In the third quarter alone, the group recorded a higher net profit of RM27.98mil as compared to RM22.57mil in the year-ago quarter. Quarterly revenue dipped to RM210.05mil from RM222.49mil in the previously comparative quarter.
"Taking into account the prevailing operating environment and the usual seasonality of the business, the group remains cautiously optimistic about delivering a satisfactory performance for the financial year ending Dec 31, 2026, barring any unforeseen circumstances," it said.
Group CEO Wan Amir-Jeffery Wan Abdul Majid said the group maintains a positive outlook for the domestic pharmaceutical industry in light of the government's ongoing policies.
"The 2.52% increase in healthcare allocation to RM47.7bil under Budget 2027, coupled with sales tax relief on eligible pharmaceutical manufacturing inputs and local equipment purchases are positive indicators for domestic pharmaceutical manufacturers.
"This complements the prioritisation of domestic manufacturing capabilities and national medicine supply security outlined under the 13th Malaysia Plan and the New Industrial Master Plan 2030,” he said in a statement.
